Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 2;21(1):290.
doi: 10.1186/s12931-020-01534-6.

Long non-coding RNA H19 deficiency ameliorates bleomycin-induced pulmonary inflammation and fibrosis

Affiliations

Long non-coding RNA H19 deficiency ameliorates bleomycin-induced pulmonary inflammation and fibrosis

Xiaoyu Wan et al. Respir Res. .

Abstract

Background: The poor understanding of pathogenesis in idiopathic pulmonary fibrosis (IPF) impaired development of effective therapeutic strategies. The aim of the current study is to investigate the roles of long non-coding RNA H19 (lncRNA H19) in the pulmonary inflammation and fibrosis of IPF.

Methods: Bleomycin was used to induce pulmonary inflammation and fibrosis in mice. The mRNAs and proteins expression in lung tissues was determined by quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. H19 knockout (H19-/-) mice were generated by CRISPR/Cas9.

Results: The expression of H19 mRNA was up-regulated in fibrotic lungs patients with IPF as well as in lungs tissues that obtained from bleomycin-treated mice. H19-/- mice suppressed bleomycin-mediated pulmonary inflammation and inhibited the Il6/Stat3 signaling. H19 deficiency ameliorated bleomycin-induced pulmonary fibrosis and repressed the activation of TGF-β/Smad and S1pr2/Sphk2 in the lungs of bleomycin-treated mice.

Conclusions: Our data suggests that H19 is a profibrotic lncRNA and a potential therapeutic target for IPF.

Keywords: Pulmonary fibrosis; S1pr2; Smad; lncRNA H19.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Fig. 1
Fig. 1
H19 increased in lungs of pulmonary fibrosis. a Data for H19 mRNA expression extracted from the GEO database, comparing whole extracts of lung tissue from human patients diagnosed with IPF (n = 50) and other interstitial lung diseases (ILD) (n = 35) and from control subjects (n = 55) (GSE47460). b Data for H19 mRNA expression extracted from the GEO microarray database, comparing whole extracts of lung tissue from bleomycin-induced lung fibrosis in rat (n = 5 animals per bleomycin-treated group and n = 22 for saline controls). c Representative images of FISH targeting H19 (red) and immunofluorescence (IF) staining of Sftpc in lungs of Sham and bleomycin-treated mice. d The relative H19 mRNA levels in the lungs of Sham wild type (Wt, n = 8), Sham H19 knockout (H19−/−, n = 6) Wt bleomycin (BLM, n = 8) and H19−/− BLM (n = 10) mice were determined by real-time RT-PCR. The Hprt1 was used as an internal control. e Representative images of the DNA agarose gels of H19 and Hprt1
Fig. 2
Fig. 2
H19 knockout inhibited bleomycin-induced pulmonary inflammation in mice. a Representative immunofluorescence (IF) images of CD45 positive cells in lungs of Sham Wt (n = 10), Sham H19−/− (n = 7), Wt BLM (n = 9) and H19−/− BLM (n = 9) mice. b The relative mRNA levels of the inflammatory marker genes including F4/80, CD11b, Ccl20, IL1b and Ym1, in the lungs of Sham Wt (n = 10), Sham H19−/− (n = 7), Wt BLM (n = 9) and H19−/− BLM (n = 9) mice. The Hprt1 was used as an internal control. c Representative images of the immune blots of Il6, p-Stat3, Stat3 and β-Actin. d Relative protein expression levels of Il6 and p-Stat3 were normalized using β-actin or Stat3. Statistical significance: *p < 0.05; **p < 0.01; ns not significant
Fig. 3
Fig. 3
H19 deficiency ameliorated bleomycin-induced pulmonary fibrosis in mice. a Representative images of hematoxylin–eosin (H&E) staining, masson’s trichrome staining, Sirius red staining and collagen I immunofluorescence staining of Sham Wt, Sham H19−/−, Wt BLM and H19−/− BLM mice. b Ashcroft score for Sham Wt (n = 10), Sham H19−/− (n = 7), Wt BLM (n = 9) and H19−/− BLM (n = 9) mice. c Quantifying collagen content with hydroxyproline assay in the lungs of Sham Wt, Sham H19−/−, Wt BLM and H19−/− BLM mice. Each group, n = 6–8. d Real-time PCR analysis for Tgfb1, Col1a1 and Acta2 in the lungs of Sham Wt, Sham H19−/−, Wt BLM and H19−/− BLM mice. Each group, n = 8–10. e Western blot analysis for collagen type I the lungs of Sham Wt, Sham H19−/−, Wt BLM and H19−/− BLM mice. f Quantification of the panel (e)
Fig. 4
Fig. 4
H19 depletion altered the TGF-β/Smads and S1pr2/Sphk2 pathways in lungs of bleomycin-induced mice. a Western blot analysis for Smad1/5, Smad2, Smad3, Samd4 and their phosphorylated forms the lungs of Sham Wt, Sham H19−/−, Wt BLM and H19−/− BLM mice. b Quantification of the panel (a). c Western blot analysis for S1pr2 and Sphk2 in the lungs of Sham Wt, Sham H19−/−, Wt BLM and H19−/− BLM mice. d Quantification of the panel (c)
Fig. 5
Fig. 5
H19 depletion reduced cell proliferation in lungs of bleomycin-induced mice. a Representative images of co-staining for Sftpc and Ki67 in the lungs of Sham Wt, Sham H19−/−, Wt BLM and H19−/− BLM mice. b Western blot analysis for Sftpc, p-Egfr, Egfr, Lin28 and β-actin in the lungs of Sham Wt, Sham H19−/−, Wt BLM and H19−/− BLM mice

Similar articles

Cited by

References

    1. King TE, Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–1961. doi: 10.1016/S0140-6736(11)60052-4. - DOI - PubMed
    1. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21:355–361. doi: 10.1183/09059180.00002512. - DOI - PMC - PubMed
    1. Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, Yi ES, Ryu JH. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010;137:129–137. doi: 10.1378/chest.09-1002. - DOI - PMC - PubMed
    1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810–816. doi: 10.1164/rccm.200602-163OC. - DOI - PubMed
    1. Travis WD, Costabel U, Hansell DM, King TE, Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–748. doi: 10.1164/rccm.201308-1483ST. - DOI - PMC - PubMed

MeSH terms